Apixaban Should NOT Be Used in Active Infective Endocarditis
Do not use apixaban (or any anticoagulation) in patients with active infective endocarditis unless there is a separate, compelling indication for anticoagulation (such as mechanical prosthetic heart valve or atrial fibrillation), and even then, the decision requires extreme caution and multidisciplinary consultation.
Key Reasoning
FDA Labeling Explicitly Excludes This Population
The FDA label for apixaban (Eliquis) states that "the safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients" 1. While this specifically addresses prosthetic valves, it reflects the broader concern about using DOACs in valvular pathology with high thrombotic and bleeding risk—which endocarditis represents.
Anticoagulation Does NOT Prevent Embolic Events in IE
The fundamental principle is that infective endocarditis alone is NOT an indication for anticoagulation 2. Research demonstrates that anticoagulation fails to reduce ischemic stroke risk in IE patients 3, 2. The embolic events in IE result from infected vegetations breaking off, not from traditional thrombus formation—anticoagulation cannot prevent this mechanical process.
Increased Bleeding Risk Outweighs Any Theoretical Benefit
Patients with IE face catastrophic bleeding complications when anticoagulated:
- Intracerebral hemorrhage occurs in ~5% of IE patients and is the leading cause of death in anticoagulated patients 4
- In prosthetic valve endocarditis, 36% of anticoagulated patients developed symptomatic cerebral hemorrhage with 80% mortality 5
- Anticoagulated patients have significantly higher rates of cerebrovascular accidents (19/94 vs 19/238, p<0.01) 6
Clinical Algorithm for Decision-Making
Step 1: Confirm IE Diagnosis
If active IE is confirmed, default position is NO anticoagulation unless compelling alternative indication exists.
Step 2: Assess for Pre-existing Anticoagulation Indications
If patient has mechanical prosthetic valve:
- Continue anticoagulation with warfarin (NOT apixaban—DOACs contraindicated) 1
- Monitor closely for bleeding complications
- Consider temporary discontinuation if intracranial hemorrhage occurs
If patient has atrial fibrillation:
- Discontinue apixaban during active IE phase 2
- Reassess need after completing antibiotic course and documenting vegetation resolution
- If stroke occurs during IE, maintain heparin anticoagulation unless hemorrhagic transformation 6
If patient on dual antiplatelet therapy (post-PCI):
- No clear data available 4
- Consider reducing to single antiplatelet agent
- Consult cardiology urgently
Step 3: Monitor for Complications
If ischemic stroke occurs during IE:
- Do NOT start anticoagulation reflexively
- Obtain urgent brain imaging to exclude hemorrhage
- If large or hemorrhagic infarct: absolutely contraindicated
- If small non-hemorrhagic infarct: consider heparin (NOT apixaban) only after infectious disease consultation 6
If intracranial hemorrhage occurs:
- Immediately discontinue all anticoagulation 1
- Apixaban effect persists 24 hours after last dose 1
- Consider reversal agent (andexanet alfa) if available
- Do not restart anticoagulation during active IE
Special Considerations
Why Not Apixaban Specifically?
- No reversal experience in IE bleeding emergencies 1
- Cannot be monitored with standard coagulation tests 1
- Contraindicated in active pathological bleeding—and IE carries high bleeding risk 1
- Not studied in prosthetic valves or IE populations 1
Single Exception: Low-Dose Aspirin
Recent evidence suggests low-dose aspirin (75-100mg) after hospitalization may reduce mortality without increasing hemorrhagic stroke 4. This is NOT the same as therapeutic anticoagulation with apixaban.
Common Pitfalls to Avoid
- Do not reflexively continue home anticoagulation when IE is diagnosed—reassess indication
- Do not start apixaban for "stroke prevention" in IE—it doesn't work and increases bleeding risk
- Do not use apixaban as bridge therapy in IE patients with mechanical valves—use heparin or warfarin only
- Do not restart anticoagulation immediately after embolic stroke in IE—obtain imaging first and consult neurology
Bottom Line
Apixaban has no role in active infective endocarditis. If the patient was on apixaban for atrial fibrillation when IE developed, stop it during the active infection phase. If they have a mechanical valve requiring anticoagulation, use warfarin instead. The only scenario where continuing anticoagulation might be considered is a patient with pre-existing mechanical prosthetic valve (using warfarin, not apixaban) who develops IE, and even then, the risk-benefit must be continuously reassessed with infectious disease and cardiology specialists 2.